Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1987 1
1988 1
1989 3
1990 3
1991 3
1992 1
1993 2
1994 4
1995 4
1996 3
1997 2
1998 1
1999 5
2000 1
2002 5
2003 6
2005 2
2006 1
2007 2
2008 16
2009 14
2010 7
2011 9
2012 13
2013 8
2014 11
2015 10
2016 17
2017 12
2018 22
2019 32
2020 19
2021 33
2022 28
2023 33
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

297 results

Results by year

Filters applied: . Clear all
Page 1
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.
Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H, Kumthekar PU, Chen CC, Aiken R, Groves MD, Ong SS, Ramakrishna R, Vogelbaum MA, Khagi S, Kaley T, Melear JM, Peereboom DM, Rodriguez A, Yankelevich M, Nair SG, Puduvalli VK, Aldape K, Gao A, López-Janeiro Á, de Andrea CE, Alonso MM, Boutros P, Robbins J, Mason WP, Sonabend AM, Stupp R, Fueyo J, Gomez-Manzano C, Lang FF, Zadeh G. Nassiri F, et al. Nat Med. 2023 Jun;29(6):1370-1378. doi: 10.1038/s41591-023-02347-y. Epub 2023 May 15. Nat Med. 2023. PMID: 37188783 Free PMC article. Clinical Trial.
Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies.
Leclercq-Cohen G, Steinhoff N, Albertí Servera L, Nassiri S, Danilin S, Piccione E, Yángüez E, Hüsser T, Herter S, Schmeing S, Gerber P, Schwalie P, Sam J, Briner S, Jenni S, Bianchi R, Biehl M, Cremasco F, Apostolopoulou K, Haegel H, Klein C, Umaña P, Bacac M. Leclercq-Cohen G, et al. Clin Cancer Res. 2023 Nov 1;29(21):4449-4463. doi: 10.1158/1078-0432.CCR-22-3667. Clin Cancer Res. 2023. PMID: 37379429 Free PMC article.
CONCLUSIONS: Our work sheds new light on the cellular and molecular players involved in cytokine release driven by TCBs and provides a rationale for the prevention of CRS in patients treated with TCBs. See related commentary by Luri-Rey et al., p. 4320....
CONCLUSIONS: Our work sheds new light on the cellular and molecular players involved in cytokine release driven by TCBs and provides a ratio …
International Tuberculum Sellae Meningioma Study: Surgical Outcomes and Management Trends.
Magill ST, Schwartz TH, Couldwell WT, Gardner PA, Heilman CB, Sen C, Akagami R, Cappabianca P, Prevedello DM, McDermott MW; International Tuberculum Sellae Meningioma Study Authors. Magill ST, et al. Neurosurgery. 2023 Dec 1;93(6):1259-1270. doi: 10.1227/neu.0000000000002569. Epub 2023 Jun 30. Neurosurgery. 2023. PMID: 37389475

GTR decreased with increased diameter (OR: 0.80 per cm, P = .0036) and preoperative visual deficits (OR 0.56, P = .0075). ...The cerebrospinal fluid leak rate was 17.3% for EEA and 2.2% for TCA (OR 9.1, P < .0001). The recurrence rate was 10.9% (n = 103).

…
GTR decreased with increased diameter (OR: 0.80 per cm, P = .0036) and preoperative visual deficits (OR 0.56, P = .0075). ...T …
Consensual Ophthalmotonic Reaction Following Selective Laser Trabeculoplasty.
Nassiri N, Mei F, Tokko H, Zeiter J, Syeda S, Kim C, Swendris R, Goyal A, Veld EI, Mas-Ramirez A, Rana SW, Juzych MS, Hughes BA. Nassiri N, et al. J Curr Glaucoma Pract. 2022 Jan-Apr;16(1):36-40. doi: 10.5005/jp-journals-10078-1361. J Curr Glaucoma Pract. 2022. PMID: 36060042 Free PMC article.
RESULTS: At all follow-up periods, the IOP of the treated eye was decreased from baseline IOP (p 0.05, paired t-test). For the fellow eye, there was a statistically significantly decrease from baseline up to the 4-9 months follow-up period (p 0.05, paired t-test). L …
RESULTS: At all follow-up periods, the IOP of the treated eye was decreased from baseline IOP (p 0.05, paired t-test). For the fellow …
IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.
Taylor CA, Watson RA, Tong O, Ye W, Nassiri I, Gilchrist JJ, de Los Aires AV, Sharma PK, Koturan S, Cooper RA, Woodcock VK, Jungkurth E, Shine B, Coupe N, Payne MJ, Church DN, Naranbhai V, Groha S, Emery P, Mankia K, Freedman ML, Choueiri TK, Middleton MR, Gusev A, Fairfax BP. Taylor CA, et al. Nat Med. 2022 Dec;28(12):2592-2600. doi: 10.1038/s41591-022-02095-5. Epub 2022 Dec 16. Nat Med. 2022. PMID: 36526722 Free PMC article.
International Tuberculum Sellae Meningioma Study: Preoperative Grading Scale to Predict Outcomes and Propensity-Matched Outcomes by Endonasal Versus Transcranial Approach.
Magill ST, Schwartz TH, Couldwell WT, Gardner PA, Heilman CB, Sen C, Akagami R, Cappabianca P, Prevedello DM, McDermott MW; International Tuberculum Sellae Meningioma Study. Magill ST, et al. Neurosurgery. 2023 Dec 1;93(6):1271-1284. doi: 10.1227/neu.0000000000002581. Epub 2023 Jul 7. Neurosurgery. 2023. PMID: 37418417

RESULTS: The M-M scale predicted visual worsening (odds ratio [OR]/point: 1.22, 95% CI: 1.02-1.46, P = .0271) and gross total resection (GTR) (OR/point: 0.71, 95% CI: 0.62-0.81, P < .0001), but not recurrence ( P = .4695). ...In propensity-matched samples,

…
RESULTS: The M-M scale predicted visual worsening (odds ratio [OR]/point: 1.22, 95% CI: 1.02-1.46, P = .0271) and gross total resecti …
Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.
Suppiah S, Mansouri S, Mamatjan Y, Liu JC, Bhunia MM, Patil V, Rath P, Mehani B, Heir P, Bunda S, Velez-Reyes GL, Singh O, Ijad N, Pirouzmand N, Dalcourt T, Meng Y, Karimi S, Wei Q, Nassiri F, Pugh TJ, Bader GD, Aldape KD, Largaespada DA, Zadeh G. Suppiah S, et al. Nat Commun. 2023 May 10;14(1):2696. doi: 10.1038/s41467-023-38432-6. Nat Commun. 2023. PMID: 37164978 Free PMC article.
CD105 Over-expression Is Associated with Higher WHO Grades for Gliomas.
Kong X, Wang Y, Liu S, Xing B, Yang Y, Li Y, Ren Z, Su C, Ma W, Wang R. Kong X, et al. Mol Neurobiol. 2016 Jul;53(5):3503-3512. doi: 10.1007/s12035-015-9677-1. Epub 2016 Feb 16. Mol Neurobiol. 2016. PMID: 26884265
They were all conducted in China, revealing that CD105 overexpression in glioma tissues was strongly linked to high WHO grading (III+IV) (SMD -1.785, 95 % CI -2.133, -1.437; p = 0.000). No significant associations between CD105 and age (SMD -0.505, 95 % CI -1.054, 0.043; …
They were all conducted in China, revealing that CD105 overexpression in glioma tissues was strongly linked to high WHO grading (III+IV) (SM …
Testicular Mesothelioma: An Analysis of Epidemiology, Patient Outcomes, and Prognostic Factors.
Nazemi A, Nassiri N, Pearce S, Daneshmand S. Nazemi A, et al. Urology. 2019 Apr;126:140-144. doi: 10.1016/j.urology.2019.01.009. Epub 2019 Jan 19. Urology. 2019. PMID: 30668959 Review.
Biphasic mesotheliomas were associated with worse OS compared to general mesotheliomas and epithelioid subtypes (P = .043 and P = .039, respectively). Median survival time was not reached in patients with T1 disease while OS was 1.7 years and DSS was 1.8 years for p …
Biphasic mesotheliomas were associated with worse OS compared to general mesotheliomas and epithelioid subtypes (P = .043 and P …
297 results